Keybank National Association Phathom Pharmaceuticals, Inc. Transaction History
Keybank National Association
- $24.5 Billion
- Q1 2025
A detailed history of Keybank National Association transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Keybank National Association holds 25,512 shares of PHAT stock, worth $102,558. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,512
Previous 25,512
-0.0%
Holding current value
$102,558
Previous $207,000
23.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$40.6 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$30 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$28.3 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$14.7 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$14.1 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $157M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...